Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice

PLoS ONE

Volumn 4, Issue 3, 2009, Pages

  Weyermann, Philipp ^a   Dallmann, Robert ^a   Magyar, Josef ^a   Anklin, Corrine ^a   Hufschmid, Martina ^a   Dubach Powell, Judith ^a   Courdier Fruh, Isabelle ^a   Henneböhle, Marco ^a   Nordhoff, Sonja ^a   Mondadori, Cesare ^a  

^a Santhera Pharmaceuticals   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR BLOCKING AGENT; MELANOCORTIN 4 RECEPTOR ANTAGONIST; SNT 207707; SNT 209858; UNCLASSIFIED DRUG; MELANOCORTIN 4 RECEPTOR;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CACHEXIA; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FOOD INTAKE; LEAN BODY WEIGHT; MALE; MOUSE; NONHUMAN; RISK REDUCTION; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BODY WEIGHT; BRAIN LEVEL; DRUG ANTAGONISM; DRUG EFFECT; EATING; HUMAN; KAPLAN MEIER METHOD; RANDOMIZATION; TUMOR CELL LINE;

AGOUTI; ANIMALIA; MUS;

ANIMALS; BODY WEIGHT; BRAIN CHEMISTRY; CACHEXIA; CELL LINE, TUMOR; EATING; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; RANDOM ALLOCATION; RECEPTOR, MELANOCORTIN, TYPE 4;

EID: 63349100316     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004774     Document Type: Article

References (34)

1. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, et al. (2008) Cachexia: A new definition. Clin Nutr 27: 793-799.
2. Tisdale MJ (2002) Cachexia in cancer patients. Nat Rev Cancer 2: 862-871.
3. Laviano A, Meguid MM, Inui A, Muscaritoli M, Rossi-Fanelli F (2005) Therapy insight: Cancer anorexia-cachexia syndrome-when all you can eat is yourself. Nat Clin Pract Oncol 2: 158-165.
4. Laviano A, Meguid MM (1996) Nutritional issues in cancer management. Nutrition 12: 358-371.
5. Mak RH, Cheung W (2006) Energy homeostasis and cachexia in chronic kidney disease. Pediatr Nephrol 21: 1807-1814.
6. Plauth M, Schutz ET (2002) Cachexia in liver cirrhosis. Int J Cardiol 85: 83-87.
7. Argiles JM, Lopez-Soriano FJ, Busquets S (2008) Novel approaches to the treatment of cachexia. Drug Discov Today 13: 73-78.
8. Celli BR, Cote CG, Lareau SC, Meek PM (2008) Predictors of Survival in COPD: more than just the FEV1. Respir Med 102 Suppl 1: S27-35.
9. Frost RA, Lang CH (2005) Skeletal muscle cytokines: regulation by pathogen-associated molecules and catabolic hormones. Curr Opin Clin Nutr Metab Care 8: 255-263.
10. O'Riordain MG, Falconer JS, Maingay J, Fearon KC, Ross JA (1999) Peripheral blood cells from weight-losing cancer patients control the hepatic acute phase response by a primarily interleukin-6 dependent mechanism. Int J Oncol 15: 823-827.
11. Puigserver P, Rhee J, Lin J, Wu Z, Yoon JC, et al. (2001) Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell 8: 971-982.
12. Ramos EJ, Suzuki S, Marks D, Inui A, Asakawa A, et al. (2004) Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care 7: 427-434.
13. Scarlett JM, Marks DL (2005) The use of melanocortin antagonists in cachexia of chronic disease. Expert Opin Investig Drugs 14: 1233-1239.
14. Tung YC, Piper SJ, Yeung D, O'Rahilly S, Coll AP (2006) A comparative study of the central effects of specific proopiomelancortin (POMC)-derived melanocortin peptides on food intake and body weight in pomc null mice. Endocrinology 147: 5940-5947.
15. Krude H, Biebermann H, Luck W, Horn R, Brabant G, et al. (1998) Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. pp 155-157.
16. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, et al. (1997) Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88: 131-141.
17. Kask A, Mutulis F, Muceniece R, Pahkla R, Mutule I, et al. (1998) Discovery of a novel superpotent and selective melanocortin-4 receptor antagonist (HS024): evaluation in vitro and in vivo. Endocrinology 139: 5006-5014.
18. Lu D, Willard D, Patel IR, Kadwell S, Overton L, et al. (1994) Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 371: 799-802.
19. Marks DL, Ling N, Cone RD (2001) Role of the central melanocortin system in cachexia. Cancer Res 61: 1432-1438.
20. Foster AC, Chen C (2007) Melanocortin-4 receptor antagonists as potential therapeutics in the treatment of cachexia. Curr Top Med Chem 7: 1131-1136.
21. Santhera Pharmaceuticals (Switzerland) AG (2008) Preparation of imidazopyridines as melanocortin-4 receptor antagonists. WO 2008/116665 A1.
22. Santhera Pharmaceuticals (Switzerland) AG (2009) Subsituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators. WO 2009/010299 A1.
23. Nicholson JR, Kohler G, Schaerer F, Senn C, Weyermann P, et al. (2006) Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice. J Pharmacol Exp Ther 317: 771-777.
24. Markison S, Foster AC, Chen C, Brookhart GB, Hesse A, et al. (2005) The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology 146: 2766-2773.
25. Joppa MA, Ling N, Chen C, Gogas KR, Foster AC, et al. (2005) Central administration of peptide and small molecule MC4 receptor antagonists induce hyperphagia in mice and attenuate cytokine-induced anorexia. Peptides 26: 2294-2301.
26. Heinrichs SC (2001) Mouse feeding behavior: ethology, regulatory mechanisms and utility for mutant phenotyping. Behavioural Brain Research 125: 81-88.
27. Foster AC, Chen C, Markison S, Marks DL (2005) MC4 receptor antagonists: a potential treatment for cachexia. IDrugs 8: 314-319.
28. Vos TJ, Caracoti A, Che JL, Dai M, Farrer CA, et al. (2004) Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. J Med Chem 47: 1602-1604.
29. Chen C, Tucci FC, Jiang W, Tran JA, Fleck BA, et al. (2008) Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Bioorg Med Chem 16: 5606-5618.
30. Konturek SJ, Konturek JW, Pawlik T, Brzozowski T (2004) Brain-gut axis and its role in the control of food intake. J Physiol Pharmacol 55: 137-154.
31. Trayhurn P, Bing C (2006) Appetite and energy balance signals from adipocytes. Philos Trans R Soc Lond B Biol Sci 361: 1237-1249.
32. Williams G, Bing C, Cai XJ, Harrold JA, King PJ, et al. (2001) The hypothalamus and the control of energy homeostasis: different circuits, different purposes. Physiol Behav 74: 683-701.
33. Hoggard N, Rayner DV, Johnston SL, Speakman JR (2004) Peripherally administered [Nle4,D-Phe7]-alpha-melanocyte stimulating hormone increases resting metabolic rate, while peripheral agouti-related protein has no effect, in wild type C57BL/6 and ob/ob mice. J Mol Endocrinol 33: 693-703.
34. Small CJ, Kim MS, Stanley SA, Mitchell JR, Murphy K, et al. (2001) Effects of chronic central nervous system administration of agouti-related protein in pairfed animals. Diabetes 50: 248-254.